Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA M1043V |
Therapy | Alpelisib |
Indication/Tumor Type | histiocytosis |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA M1043V | histiocytosis | predicted - sensitive | Alpelisib | Case Reports/Case Series | Actionable | In a clinical case study, Piqray (alpelisib) treatment resulted in symptom improvement and a complete metabolic response lasting at least 9 months in a patient with Langerhans cell histiocytosis harboring PIK3CA M1043V (PMID: 37874915). | 37874915 |
PubMed Id | Reference Title | Details |
---|---|---|
(37874915) | Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. | Full reference... |